Copenhagen, Denmark - 28 October, 2011 - Today Topotarget A/S (NASDAQ OMX:
TOPO.CO) and Multimeric Biotherapeutics, Inc. (Multimeric) announced the
signature of an exclusive license agreement granting Multimeric rights to the
further development of the multimeric TNF superfamily ligands (TNFSFs) for all
therapeutic uses. TNFSFs are not a core activity of Topotarget IP assets.
Topotarget continue to focus efforts on its lead compound the HDACi belinostat.
Under the agreement, Multimeric will license the rights to all multimeric
fusion proteins containing TNFSFs which are covered by Topotarget's issued and
pending patents in Europe, US, Canada, Japan, Australia, South Korea, and other
territories. The agreement also grants Multimeric the rights to sub-license.

“This agreement unifies the patent estates of our two companies for the
therapeutic applications of the TNFSFs (other than FasL),” said Dr. Richard S.
Kornbluth, President and Chief Scientific Officer of Multimeric. The key to the
technology is a means for producing TNFSFs as highly active, many-trimer
proteins. Included in the agreement are multimeric forms of CD40 ligand
(CD40L), GITR ligand (GITRL), and other TNFSFs that are the subject of much
current scientific and medical interest.

“By concluding this deal Topotarget is able to complement Multimeric's IP
portfolio thereby enabling their continued global development within the
TNFSFs' field”, said Inge Lauritzen, VP of Business Development and Licensing
at Topotarget.

No details on the terms of the agreement were disclosed.

Today's news does not change Topotarget's full-year financial guidance for 2011.


Topotarget A/S


For further information, please contact:

Annette Lykke, IR Direct: +45 39 17 83 44; Mobile: +45
23 28 98 14


Background information

About Multimeric

Multimeric Biotherapeutics, Inc., a Delaware corporation was spun out of
technology developed by Dr. Kornbluth when he was at the University of
California San Diego. Multimeric's lead products include immunotherapy
protocols for cancer and vaccines against chronic viral infections. The company
is privately held and is supported by its founders, angel investors, and NIH
grants. It has offices in La Jolla, CA and laboratories at the San Diego
Science Center in San Diego, CA. For more information, please refer to
www.multimericbio.com.

About Topotarget

Topotarget (NASDAQ OMX: TOPO.CO) is a Scandinavian-based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti-neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of chemotherapy, and is currently in a pivotal trial within PTCL
(peripheral T-cell lymphoma) and phase II in cancer of unknown primary site
(CUP). Topotarget's cancer drug target is HDAC. Totect® is a product on the
market developed from Topotarget's drug discovery technology. Totect® is
marketed by the company's own sales specialists in the US. The European rights
to Savene® were divested in March 2010 as a consequence of the focus to develop
and commercialize belinostat. For more information, please refer to
www.topotarget.com.

Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrollment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

Investor news no. 04-11 Topotarget grants Multimeric Biotherapeutics exclusive license to TNFSFs.pdf